Multiple sclerosis (MS) is a chronic autoimmune neurodegenerative disease characterized by immune-mediated destruction of central nervous system (CNS) myelin, leading to progressive neuroaxonal loss and neurological disability. Despite being traditionally classified as an autoimmune disease, emerging evidence demonstrates that neurodegenerative processes play a critical role in disease progression, with significant overlap between MS mechanisms and other neurodegenerative conditions including Alzheimer's disease and Parkinson's disease. [1]
The pathogenesis of MS involves a complex interplay between adaptive and innate immune responses, resident glial cells, and neuronal/axonal elements. Understanding these mechanisms is essential for developing disease-modifying therapies that target both inflammatory and neurodegenerative components of the disease. [2]
The inflammatory cascade in MS is initiated by activation of myelin-reactive T lymphocytes in the peripheral immune system. CD4+ T helper cells, particularly Th1 and Th17 subsets, play pivotal roles in disease initiation and propagation: [3]
The activation of these T cell subsets requires recognition of myelin antigens presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells, particularly dendritic cells in peripheral lymphoid tissues. [4]
B cells play a dual role in MS pathogenesis through antibody production and antigen presentation: [5]
Microglia and astrocytes represent the innate immune arm of the CNS and are critical players in MS pathology: [6]
The hallmark pathological feature of MS is focal demyelination within the CNS white matter. Multiple mechanisms contribute to myelin loss: [7]
Oligodendrocytes, the myelin-producing cells of the CNS, are targeted through multiple mechanisms: [8]
Although spontaneous remyelination occurs in early MS lesions, this process fails in chronic lesions. Contributing factors include: [9]
Neuroaxonal degeneration occurs early in MS and correlates with irreversible neurological disability. Multiple mechanisms contribute to axonal injury: [10]
Neuronal cell bodies are lost in both gray and white matter regions: [11]
The neurodegenerative component of MS shares mechanisms with other neurodegenerative diseases: [12]
BBB disruption is a critical early event in MS pathogenesis: [13]
Genome-wide association studies (GWAS) have identified over 230 genetic risk loci for MS, many involved in immune function: [14]
Approximately 85% of patients present with RRMS, characterized by discrete attacks (relapses) followed by partial or complete recovery (remissions). During relapses, acute inflammatory demyelination produces focal neurological deficits. [15]
Most RRMS patients eventually transition to SPMS, characterized by gradual progression of disability independent of acute flares. SPMS involves predominantly neurodegenerative mechanisms with diminished inflammatory activity.
Approximately 15% of patients experience progressive disability from onset, with less prominent inflammatory activity and poorer response to immunomodulatory therapies.
CIS represents a first demyelinating event, often preceding diagnosis of clinically definite MS. Many CIS patients convert to MS within years.
Current MS therapies primarily target the inflammatory component:
| Drug Class | Example | Mechanism |
|---|---|---|
| Interferon-beta | IFN-β1a, IFN-β1b | Immunomodulation, BBB stabilization |
| Glatiramer acetate | Copolymer-1 | Myelin antigen modification |
| Natalizumab | Anti-α4 integrin | Block T cell CNS entry |
| Fingolimod | S1P receptor modulator | Sequester lymphocytes in lymph nodes |
| Ocrelizumab | Anti-CD20 B cell depletion | Reduce B cell-mediated immunity |
| Alemtuzumab | Anti-CD52 | Deplete T and B cells |
Emerging therapies aim to address neurodegeneration:
MS shares several pathological mechanisms with other neurodegenerative conditions:
Understanding these common pathways may lead to shared therapeutic approaches across neurodegenerative diseases.
Multiple sclerosis represents a complex interplay between autoimmune inflammation and neurodegenerative processes. While current therapies effectively target the inflammatory component, addressing neuroaxonal degeneration remains a critical unmet need. Continued research into disease mechanisms, particularly the intersection of neuroinflammation and neurodegeneration, will be essential for developing therapies that prevent irreversible disability progression.
" Sawcer S, Franklin RJ, Hanemann M. Multiple sclerosis. Nat Rev Neurol. 2014;10(6):305-306". 2014. ↩︎
Ciccarelli O, Barkhof F, Bodini B, et al. 'Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol. 2014;13(8):807-822'. 2014. ↩︎
" Geurts JJ, Calabrese M, Fisher E, Rudick RA. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol. 2012;11(12):1082-1092". 2012. ↩︎
Trapp BD, Peterson J, Ransohoff RM, et al. " Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278-285". 1998. ↩︎
'Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol. 2001;14(3):271-278'. 2001. ↩︎
Frischer JM, Bramow S, Dal-Bianco A, et al. " The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(Pt 5):1175-1189". 2009. ↩︎
" Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683-747". 2005. ↩︎
" Kurtzke JF. Epidemiology of multiple sclerosis. Handb Clin Neurol. 2014;122:275-297". 2014. ↩︎
Roxburgh RH, Seaman SR, Masterman T, et al. 'Multiple Sclerosis Severity Score: using disability and disease duration to set disease severity. Neurology. 2005;64(7):1144-1151'. 2005. ↩︎
'Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010;9(5):A387-A394'. 2010. ↩︎
'Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: findings from case-control studies. Ann Neurol. 2007;62(3):201-214'. 2007. ↩︎
Bar-Or A, Rieckmann P, Trajkovic A, et al. " Targeting immune processes in multiple sclerosis. Nat Rev Neurol. 2021;17(11):681-698". 2021. ↩︎
Coles AJ, Wing MG, Molyneux P, et al. " Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1999;67(3):352-357". 1999. ↩︎
Hauser SL, Bar-Or A, Comi G, et al. " Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234". 2017. ↩︎
Kappos L, Bar-Or A, Cree B, et al. 'Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273'. 2018. ↩︎